Thalidomide for de novo Crohn's disease after ileal pouch anal anastomosis for ulcerative colitis.

De novo Crohn's disease (CD) is an increasingly reported diagnosis after ileal pouch anal anastomosis (IPAA). Currently, no consensus exists on the best treatment strategy. This report details the case of a 5-year-old child with early-onset ulcerative colitis (UC) who developed findings compatible with CD 12 months after IPAA. Thalidomide therapy led to clinical and endoscopic remission without side effects at 6 months. To our knowledge, this is the first report of thalidomide for treatment of de novo CD. Thalidomide therapy could be considered in patients with de novo CD, with similar indications of CD. © 2020 John Wiley & Sons Ltd.

Citation

Valeria Dipasquale, Angelo Tropeano, Flavia Caime, Claudio Romano. Thalidomide for de novo Crohn's disease after ileal pouch anal anastomosis for ulcerative colitis. Journal of clinical pharmacy and therapeutics. 2020 Aug;45(4):819-821

Mesh Tags

Substances

PMID: 32298484

search → result